Xcout IntelAgomAb Therapeutics NV
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Subscribe to see AgomAb Therapeutics NV’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AgomAb Therapeutics NV at a glance
AgomAb Therapeutics NV is a biotech company headquartered in Antwerp, Belgium. It is publicly listed (AGMB) with a market capitalisation of $714.1M. Xcout tracks 14 named people at AgomAb Therapeutics NV, including Tim Knotnerus (CEO & Executive Director).
AgomAb Therapeutics NV leadership
- Tim KnotnerusCEO & Executive Director
- Pierre KemulaChief Financial Officer
- Andrea SáezChief Development Officer
- Andrea Sáez BorderíasChief Development Officer
- Paul Van Der HorstChief Business Officer
- Philippe WieselChief Medical Officer
8 more named people on record for AgomAb Therapeutics NV, with roles, board committees and tenure — see the full roster →
Recent AgomAb Therapeutics NV news
4 corporate events on record, with sources — see the full timeline →
AgomAb Therapeutics NV competitors
A few of AgomAb Therapeutics NV's closest competitors — see the full list of competitors and alternatives →
Chemomab is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. Based in Tel Aviv, Israel, the company builds its treatments on unique scientific insights.
Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
FNC Biotech is a biotechnology company established in 2021 that focuses on the development of antibody therapeutics for idiopathic pulmonary fibrosis and cancer.
Alentis Therapeutics is a Swiss biotechnology company developing antibody-based medicines that target Claudin-1 (CLDN1), a protein involved in tumor biology and tissue fibrosis. Its therapies are intended for patients with solid tumors and fibrotic diseases, including liver and other organ fibrosis.
Get AgomAb Therapeutics NV's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AgomAb Therapeutics NV in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access